Beauvais David, Bachy Emmanuel, Baruchel André, Bay Jacques-Olivier, Caillot Denis, Cartron Guillaume, Damaj Gandhi, Furst Sabine, Le Gouill Steven, Morschhauser Franck, Rabian Florence, Rubio Marie-Thérèse, Thieblemont Catherine, Yakoub-Agha Ibrahim
CHU de Lille, université de Lille, hôpital Huriez, service des maladies du sang, Lille, France.
Hôpital Lyon Sud, Université Lyon 1 Claude Bernard, service d'hématologie clinique, Pierre-Bénite, France.
Bull Cancer. 2021 Jul-Aug;108(7-8):725-729. doi: 10.1016/j.bulcan.2020.10.017. Epub 2021 Jan 7.
The chimeric antigen receptor T-cells are a new class of anticancer treatment consisting in genetically modifying autologous or allogenic T-cells to make express a CAR directed against a membrane tumor antigen. In Europe, tisagenlecleucel (Kymriah) has a marketing authorization for the treatment of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia in children and young adults and of R/R diffuse large B-cell lymphoma (DLBCL). The marketing authorization for axicabtagene ciloleucel (Yescarta) is the treatment of DLBCL and primary R/R mediastinal B-cell lymphoma. The two products are autologous T-cells directed against CD19. This collaborative work, part of a series of expert opinion-based work, aims to give practical advice to help centers in selection of patients for commercially available CAR T-cell treatment.
嵌合抗原受体T细胞是一类新型抗癌治疗方法，其原理是对自体或异体T细胞进行基因改造，使其表达针对膜肿瘤抗原的嵌合抗原受体（CAR）。在欧洲，替沙格宁（Kymriah）已获得上市许可，用于治疗儿童和年轻成人复发/难治性（R/R）B细胞急性淋巴细胞白血病以及R/R弥漫性大B细胞淋巴瘤（DLBCL）。阿基仑赛（Yescarta）的上市许可是用于治疗DLBCL和原发性R/R纵隔B细胞淋巴瘤。这两种产品都是针对CD19的自体T细胞。这项合作研究是一系列基于专家意见的工作的一部分，旨在提供实用建议，帮助各中心为商业可用的CAR T细胞治疗选择合适的患者。
